Introduction
============

Since van den Berghe and colleagues demonstrated in the second Leuven study that severe hypoglycemia (blood glucose (BG) \< 40 mg/dl) is associated with mortality \[[@B1]\], subsequent multicentre studies (Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP) and GLUCONTROL trials) have identified a high rate of severe hypoglycemic events among intensive insulin treatment (IIT) groups (target, 80 to 110 mg/dl) \[[@B2],[@B3]\]. In addition, several large observational studies have shown that severe hypoglycemia is an independent risk factor for mortality \[[@B4]-[@B6]\].

Several recent studies have demonstrated the relationship between mild hypoglycemia and increased mortality rate in critically ill patients. Egi and colleagues reported that patients with mild hypoglycemia had an increased unadjusted mortality rate \[[@B7]\], and Krinsley and colleagues also demonstrated a strong association between mild hypoglycemia and increased mortality \[[@B8]\]. The American Diabetes Association revised the definition of hypoglycemia as BG \< 70 mg/dl in 2010 \[[@B9]\]. Physicians should thus be cautious of mild hypoglycemic events when treating critically ill patients.

Glucose control may be difficult in patients with sepsis because of frequent hypoglycemic and hyperglycemic events, which can have detrimental effects on hospital outcomes \[[@B10]-[@B12]\]. Although many glucose control studies have included patients with sepsis \[[@B2],[@B3],[@B7],[@B13]\], the importance of hypoglycemia among patients with sepsis has been addressed by only a few studies \[[@B11],[@B14]\]. In particular, data on mild hypoglycemia are limited. The primary objective of this study was therefore to investigate the association between mild hypoglycemia (BG 40 to 69 mg/dl) and hospital mortality, and the secondary objectives were to investigate its relationship with the ICU-acquired complication rate and ICU and 1-year mortality rates among patients with sepsis.

Materials and methods
=====================

Study population
----------------

Patients who were admitted to the medical ICU for sepsis at Hallym University Sacred Heart Hospital between January 2008 and December 2010 were enrolled in our study. The 2008 Surviving Sepsis Campaign guidelines were used to diagnose sepsis \[[@B15]\]. We collected data anonymously from electronic medical records and analyzed them retrospectively. Initially, 403 adult patients were screened for participation in the study. Patients who had daily BG tests and at least four BG tests during their ICU stay were included in the study, and 90 patients were excluded based on the exclusion criteria (Figure [1](#F1){ref-type="fig"}). The institutional review board at Hallym University Sacred Heart Hospital approved the present study (IRB No. 2012-I006) and waived the necessity to obtain written consent because of its retrospective nature.

![**Flow chart of patient enrolment**. BG, blood glucose; CPR, cardiopulmonary resuscitation.](cc11674-1){#F1}

Data collection
---------------

We collected data regarding age, sex, co-morbidities, laboratory parameters, Simplified Acute Physiology Score (SAPS) II and ICU treatments (that is, insulin, any dose of systemic steroid, mechanical ventilation, renal replacement therapy). In addition to ICU-acquired complications occurring after ICU day 3, we investigated hospital, ICU, and 30-day mortalities and 1-year cumulative survival rates.

Various BG control parameters during the ICU stay were calculated for each patient as follows: frequency of BG tests (total and daily mean frequencies); mean BG levels; number of severe hypoglycemia (BG \< 40 mg/dl) and mild hypoglycemia (BG 40 to 69 mg/dl) events; and three glucose variability (GV) parameters (standard deviation (SD) of mean BG levels, coefficient of variation (SD of mean BG/mean BG), and Hermanides\' metric for GV) \[[@B16]\]

We investigated the occurrence of ICU-acquired complications occurring after ICU day 3 (that is, renal, cardiac, hepatic and respiratory complications, and bacteremia). Renal complications were defined as: an increase in serum creatinine levels of at least twofold over baseline levels; progression of oliguria (urine output \< 500 ml in 24 hours or \< 0.5 ml/kg/hour); or initiation of renal replacement therapy.

Cardiac complications were defined as: an ischemic event indicated by an increase in cardiac markers (troponin I and creatine kinase-MB) and significant electrocardiogram changes indicative of sustained new ischemia (ST-segment depression or elevation, new pathologic Q waves, and T-wave abnormalities in at least two consecutive leads); fatal arrhythmia (ventricular tachycardia or ventricular fibrillation); or sudden cardiac arrest.

Hepatic complications were defined as: greater than twofold increase in total bilirubin over baseline levels (and at least \> 4 mg/dl); or increase in aspartate aminotransferase or alanine aminotrasferase \> 1,000 IU/l with a rise in the prothrombin time (international normalized time \> 2).

Respiratory complications were defined as: development of acute respiratory distress syndrome \[[@B17]\]; ventilator-associated pneumonia \[[@B18]\]; or initiation of mechanical ventilation after 3 ICU days, excluding cases of reintubation resulting from extubation failure.

Finally, bacteremia was defined as at least two positive blood culture results, excluding isolation of coagulase-negative *Staphylococcus*.

Blood glucose control and monitoring in the ICU
-----------------------------------------------

In our medical ICU, BG controls were conducted using an insulin protocol (Additional file [1](#S1){ref-type="supplementary-material"}) that was modified according to the Surviving Sepsis Campaign guidelines \[[@B15],[@B19]\]. The target for BG control was 70 to 150 mg/dl, and BG levels in arterial or capillary blood were measured using a bedside glucose meter (LifeScan, Inc., Milpitas, CA, USA). Patients received a continuous intravenous insulin infusion when BG levels were \> 150 mg/dl. One unit of regular human insulin per 1 ml of 0.9% NaCl was administered, and the insulin dose was adjusted to maintain the target BG level. BG values were initially monitored every 1 to 2 hours until glucose values and insulin infusion rates were stable, and then every 4 to 6 hours thereafter.

Data analyses
-------------

The primary outcome of the present study was the association between mild hypoglycemia and hospital mortality. The secondary outcomes included a comparison of ICU-acquired complication rates, and ICU and 30-day and 1-year mortalities between patients with and without mild hypoglycemia. Risk factors for hypoglycemic events were investigated, and the proportion of patients who experienced hypoglycemic events were also compared among the quartile groups of BG control parameters (that is, mean BG, SD, coefficient of variation, and Hermanides\' metric).

Data are expressed as mean (standard deviation) or median (interquartile range) as appropriate for continuous data and as percentages for categorical data. For continuous data, Student\'s *t*test or the Mann-Whitney *U*test was used when comparing two groups and analysis of variance or the Kruskal-Wallis test was used when comparing three groups. The chi-squared test or Fisher\'s exact test was used for categorical data; however, when comparing two groups from the hypoglycemia groups (that is, mild hypoglycemia vs. no hypoglycemia; severe hypoglycemia vs. no hypoglycemia), logistic regression analysis was used in which the hypoglycemia variable was categorized into three groups. To identify risk factors for hospital mortality and hypoglycemic events, multivariate logistic regression analyses were performed using covariates with *P*\< 0.05 in the univariate analyses. A backward stepwise analysis (based on the likelihood ratio) was used, with *P*= 0.05 to enter and *P*= 0.10 to stay in the model. The Kaplan-Meier method with the log-rank test was used to analyze 1-year survival rates. All reported *P*values were two-sided, and *P*\< 0.05 was considered statistically significant. All analyses were conducted using SAS statistical software, EG version (SAS Institute, Inc., Cary, NC, USA).

Results
=======

Study population
----------------

The mean age of the enrolled patients (*n*= 313) was 71.8 ± 11.3 years, and 166 were male (Table [1](#T1){ref-type="table"}). A history of smoking was found for 74 (23.6%) patients, and diabetes (*n*= 102, 32.6%) and hypertension (*n*= 125, 39.9%) were the most common co-morbid illnesses (cancer, *n*= 63; cerebrovascular accidents, *n*= 53; chronic heart disease, *n*= 35; chronic kidney disease, *n*= 36; liver cirrhosis, *n*= 14; chronic obstructive pulmonary disease/bronchial asthma, *n*= 25).

###### 

Glucose control parameters, treatments, and outcomes among enrolled patients stratified by minimum blood glucose levels

                                       Minimum blood glucose level   ***P*value**^**a**^                                   
  ------------------------------------ ----------------------------- -------------------------- -------------------------- -----------------
  Age                                  71.9 ± 11.2                   69.3 ± 12.6                72.4 ± 11.0                0.177^b^
  Male/female                          11/13                         34/22                      121/112                    0.379^c^
  Diabetes                             10 (41.7%)                    31 (55.4%)                 61 (26.2%)                 \< 0.001^c^
  Admission SAPS II                    57 ± 15.9                     52.2 ± 14.0                46.4 ± 13.1                \< 0.001^b^
  Laboratory parameters                                                                                                    
   WBC (mm^3^)                         11,550 (6,950 to 20,775)      13,450 (6,225 to 20,075)   14,300 (8,850 to 21,050)   0.053^d^
   Hematocrit (%)                      32.2 ± 6.0                    31.1 ± 7.8                 34.8 ± 6.7                 0.001^b^
   Platelet (×10^3^mm^3^)              166.0 (73.8 to 268.3)         190.0 (101.0 to 288.3)     209.0 (121.0 to 288.0)     0.320^d^
   Lactate (mmol/l)                    4.8 (3.5 to 8.6)              4.5 (2.6 to 7.0)           3.5 (2.3 to 5.6)           0.013^d^
   Serum albumin (g/dl)                2.9 ± 0.6                     3.0 ± 0.6                  3.2 ± 0.6                  0.020^b^
   Blood urea nitrogen (mg/dl)         28.3 (17.8 to 41.3)           36.6 (18.1 to 50.7)        25.6 (16.4 to 42.3)        0.237^d^
   Creatinine (mg/dl)                  1.1 (0.7 to 2.5)              1.3 (0.9 to 2.3)           1.2 (0.8 to 1.9)           0.345^d^
   Total bilirubin (mg/dl)             0.9 (0.6 to 1.4)              0.9 (0.5 to 1.7)           0.9 (0.6 to 1.9)           0.744^d^
   BNP (pg/ml)                         554.4 (207.3 to 1205.4)       347.3 (133.8 to 1377.4)    251.9 (138.8 to 638.2)     0.029^d^
   CK-MB (ng/ml)                       3.9 (2.0 to 7.9)              2.3 (1.3 to 8.2)           2.0 (0.9 to 4.95)          0.023^d^
   C-reactive protein (mg/l)           170.9 (77.3 to 232.1)         142.0 (86.9 to 225.0)      157.0 (81.6 to 239.5)      0.931^d^
  BG control parameters                                                                                                    
   Number of BG tests (/day/patient)   6.3 (4.9 to 9.9)              6.4 (5.0 to 7.9)           5.2 (4.3 to 6.7)           \< 0.001^d^
   Mean BG (mg/dl)^e^                  163.9 (146.0 to 194.3)        189.3 (166.9 to 208.1)     174.6 (145.0 to 205.9)     0.096^d^
   Median SD (mg/dl)                   73.1 (48.9 to 116.2)          71.3 (46.1 to 92.9)        42.1 (30.5 to 62.0)        \< 0.001^d^
   Median CV (%)                       41.6 (29.4 to 56.5)           37.6 (29.2 to 45.2)        24.2 (18.9 to 31.8)        \< 0.001^d^
   Hermanides\' metric (mg/dl)         11.9 (6.9 to 22.1)            11.7 (8.0 to 16.0)         6.6 (4.5 to 9.6)           \< 0.001^d^
  Insulin therapy                      18 (75.0%)                    43 (76.8%)                 142 (60.9%)                0.015^c,\ f^
  Systemic steroid therapy             9 (37.5%)                     26 (46.4%)                 91 (39.1%)                 0.576^c,\ f^
  Vasopressors                         23 (95.8%)                    45 (80.4%)                 166 (71.2%)                0.017^c,\ f^
  Mechanical ventilation               23 (95.8%)                    40 (71.4%)                 132 (56.7%)                \< 0.001^c,\ f^
  VAP                                  3 (12.5%)                     6 (10.7%)                  7 (3.0%)                   0.015^c,\ f^
  Renal replacement therapy            5 (20.8%)                     11 (19.6%)                 25 (10.7%)                 0.150^c^
  Length of ICU stay (days)            11.5 (3.3-19.8)               7.0 (5.0-14.0)             5.0 (3.0-9.0)              \< 0.001^d^
  ICU mortality                        18/24 (75.0%)                 34/56 (60.7%)              66/233 (28.3%)             \< 0.001^c,\ f^
  Hospital mortality                   19/24 (79.2%)                 37/56 (66.1%)              71/233 (30.5%)             \< 0.001^c,\ f^
  30-day mortality                     18/24 (75.0%)                 34/55 (61.8%)              69/230 (30.0%)             \< 0.001^c,\ f^
  1-year mortality                     21/24 (87.5%)                 41/55 (74.5%)              107/230 (46.5%)            \< 0.001^c,\ f^

Continuous data expressed as mean ± standard deviation or median (interquartile range) and categorical data expressed as number (%). BG, blood glucose; BNP, brain natriuretic peptide; CK-MB, creatine kinase-MB; CV, coefficient of variation; SAPS, Simplified Acute Physiology Score; SD, standard deviation; VAP, ventilator-associated pneumonia; WBC, white blood cell. ^a^Comparisons among three groups (that is, \< 40 mg/dl vs. 40 to 69 mg/dl vs. ≥ 70 mg/dl). ^b^Analysis of variance. ^c^Chi-squared test. ^d^Kruskal-Wallis test. ^e^Median values of individual mean BG levels. ^f^*P*\< 0.05 by linear-by-linear association.

Septic shock accounted for 59.4% of the patients (*n*= 186; severe sepsis, *n*= 99; sepsis, *n*= 28), and among the sepsis origins pneumonia (*n*= 171, 54.6%) was the most common (urinary tract, *n*= 58; hepatobiliary, *n*= 55; intra-abdominal, *n*= 14; soft tissue and skin, *n*= 8; bacteremia, *n*= 3; meningitis, *n*= 2; unidentified, *n*= 2). Insulin therapy was conducted in 83 (81.4%) diabetics (vs. 120 (56.9%) nondiabetics).

Blood glucose measurements, hypoglycemic events, and risk factors
-----------------------------------------------------------------

The total number of BG tests performed in all enrolled patients during their ICU stay was 14,249, and the median (interquartile range) number of BG tests per day per patient was 5.6 (4.4 to 7.0). The median value of individual mean BG levels was 177.3 mg/dl (148.8 to 205.6 mg/dl). The median values for the SD, coefficient of variation, and Hermanides\' metric were 48.4 mg/dl (33.6 to 71.0 mg/dl), 27.6% (20.0 to 36.5%), and 7.4 mg/dl (4.9 to 11.8 mg/dl), respectively. In total, 175 hypoglycemic events (BG \< 70 mg/dl) occurred in 80 (25.6%) patients. Among these, 71 (40.6%) hypoglycemic events occurred spontaneously and 104 (59.4%) occurred with insulin therapy (that is, iatrogenic hypoglycemia). A total of 83 (47.4%) events occurred in conscious patients and 92 (52.6%) events occurred in unconscious patients. Among the 80 hypoglycemic patients, 56 had a minimum BG level of 40 to 69 mg/dl (that is, mild hypoglycemia) and 24 had a minimum BG level \< 40 mg/dl (that is, severe hypoglycemia); 13 patients had both mild and severe hypoglycemia during their ICU stay.

When the patients were stratified based on their minimum BG levels, the frequency of diabetes and insulin treatment, SAPS II, SD of the mean BG, coefficient of variation, and Hermanides\' metric were higher in the two hypoglycemic groups as compared with patients without hypoglycemia (Table [1](#T1){ref-type="table"}). The frequency of hypoglycemic events tended to increase in patients with higher GV parameters (Figure [2](#F2){ref-type="fig"}).

![**Frequencies of hypoglycemia during ICU stay stratified by quartiles of glucose control parameters**. Quartile ranges of mean blood glucose (BG): \< 148.8, 148.8 to 177.3, 177.3 to 205.6, and \> 205.6 mg/dl. Quartile ranges of standard deviation (SD): \< 33.6, 33.6 to 48.4, 48.4 to 71.0, and \> 71.0 mg/dl. Quartile ranges of coefficient of variation (CV): \< 20.0%, 20.0 to 27.6%, 27.6 to 36.5%, and \> 36.5%. Quartile ranges of Hermanides\' metric: \< 4.9, 4.9 to 7.4, 7.4 to 11.8, and \> 11.8 mg/dl. ^a^*P*\< 0.001 (chi-squared test), ^b^*P*\< 0.001 (linear-by-linear association) among the quartile groups.](cc11674-2){#F2}

The univariate analyses revealed 16 variables - diabetes, hematocrit, lactate, serum albumin, brain natriuretic peptide, creatine kinase-MB, GV parameters (SD of mean BG, coefficient of variation, Hermanides\' metric), SAPS II, insulin therapy, vasopressor, mechanical ventilation, renal replacement therapy, hepatic failure, and ventilator-associated pneumonia - that were significantly associated with hypoglycemic events (*P*\< 0.05). Multivariate logistic analysis included 14 variables; of the three GV parameters, only the SD of mean BG was included in the model. Among the variables included in the final model, diabetes, hematocrit, lactate, SD of mean BG, hepatic failure, and ventilator-associated pneumonia were independent risk factors for hypoglycemic events (Table [2](#T2){ref-type="table"}).

###### 

Multivariate analysis of risk factors for hypoglycemic events

  Variable           Odds ratio   95% confidence interval   *P*value
  ------------------ ------------ ------------------------- ----------
  Diabetes           2.60         1.30 to 5.17              0.007
  Hematocrit (%)     0.91         0.87 to 0.96              0.001
  Lactate (mmol/l)   1.11         1.02 to 1.21              0.017
  CK-MB (ng/ml)      1.02         1.00 to 1.05              0.050
  SD of mean BG      1.03         1.02 to 1.04              \< 0.001
  Hepatic failure    3.63         1.52 to 8.67              0.004
  VAP                11.39        3.43 to 37.85             \< 0.001

BG, blood glucose; CK-MB, creatine kinase-MB; SD, standard deviation; VAP, ventilator-associated pneumonia. Chi-square = 5.336 and *P*= 0.721 by Hosmer-Lemeshow goodness-of-fit test.

Mild hypoglycemic events and the occurrence of ICU-acquired complications
-------------------------------------------------------------------------

We investigated the occurrence of ICU-acquired complications among 219 patients who stayed in the ICU for more than 3 days, and 202 complications occurred in 116 (53%) patients (renal, *n*= 47; cardiac, *n*= 35; hepatic, *n*= 50; respiratory, *n*= 53; bacteriemia, *n*= 17; Figure [3](#F3){ref-type="fig"}). The complication rates were higher in both hypoglycemic groups (mild hypoglycemia, 33/47; severe hypoglycemia, 15/18) as compared with patients without hypoglycemia (68/154; *P*= 0.002 and *P*= 0.005, respectively). The frequencies of renal, cardiac, and hepatic complications and bacteremia were higher in patients with mild hypoglycemia as compared with those who were not hypoglycemic (36.2% vs. 15.6%, *P*= 0.003; 31.9% vs. 14.3%, *P*= 0.008; 34.0% vs. 18.2%, *P*= 0.024; and 14.9% vs. 4.5%, *P*= 0.021, respectively). Among 48 patients with both hypoglycemia and ICU-acquired complications, hypoglycemic events occurred prior to ICU-acquired complications in 31 patients.

![**Frequency of ICU-acquired complications in patients with ICU stay \> 3 days**. Data stratified by minimum blood glucose (BG) levels. The frequencies of renal, cardiac, and hepatic complications and bacteremia were significantly higher in patients with mild hypoglycemia as compared with those without hypoglycemia. ^a^Comparisons between patients with mild hypoglycemia and those without hypoglycemia. ^b^Comparisons between patients with severe hypoglycemia and those without hypoglycemia.](cc11674-3){#F3}

Mild hypoglycemia and mortality
-------------------------------

The ICU, hospital, 30-day, and 1-year mortalities were higher in patients with mild hypoglycemia compared with those without hypoglycemia. We found an increasing trend of mortality in patients with increasing severity of hypoglycemia (Table [1](#T1){ref-type="table"}). Furthermore, we observed a trend of increasing mortality in patients with the highest frequency (0 vs. 1 to 2 vs. ≥ 3) of hypoglycemia events, irrespective of whether the hypoglycemia was mild or severe (Additional file [2](#S2){ref-type="supplementary-material"}). We also found no significant differences between spontaneous and iatrogenic hypoglycemia in terms of the time from ICU admission to hypoglycemic event, time from hypoglycemic event to hospital death, and hospital mortality rate (Table [3](#T3){ref-type="table"}).

###### 

Comparisons of time to events and time to hospital deaths among three hypoglycemic groups

  Variable                                                      Spontaneous hypoglycemia (patient *n*= 32)   Iatrogenic hypoglycemia (patient *n*= 41)   Both hypoglycemias (patient *n*= 7)   ***P*value**^**a**^
  ------------------------------------------------------------- -------------------------------------------- ------------------------------------------- ------------------------------------- ---------------------
  Total number of hypoglycemic events                           61                                           81                                          33^b^                                 
  Hospital deaths                                               22 (68.8%)                                   28 (68.3%)                                  6 (85.7%)                             0.967^c^
  Time from ICU admission to first hypoglycemic event (days)    3.0 (1.0 to 5.8)                             3.0 (1.0 to 5.5)                            1.0 (6 hours to 4.0)                  0.490^d^
  Time from first hypoglycemic event to hospital death (days)   3.0 (1.0 to 12.0)                            5.0 (1.0 to 11.5)                           13.5 (6.0 to 26.5)                    0.898^d^

^a^Comparisons between two groups (that is, spontaneous hypoglycemia vs. iatrogenic hypoglycemia). ^b^Ten hypoglycemic events occurred spontaneously. ^c^Chi-squared test. ^d^Mann-Whitney *U*test.

In the multivariate analysis, 16 variables significant at *P*\< 0.05 in the univariate analyses (Additional file [3](#S3){ref-type="supplementary-material"}) were initially included. Among the three GV parameters, the SD of the mean BG was the only variable included in the model, and the hypoglycemia variable was categorized into three groups based on minimum BG levels. In the final model (Table [4](#T4){ref-type="table"}), mild hypoglycemia was significantly associated with increased hospital mortality (odds ratio, 3.43; 95% confidence interval, 1.51 to 7.82). We performed a further multivariate analysis in patients who experienced no or one mild hypoglycemic event (*n*= 233 and 32, respectively; Additional file [4](#S4){ref-type="supplementary-material"}) and determined that a single mild hypoglycemic event was significantly associated with increased hospital mortality (OR, 2.98; 95% confidence interval, 1.10 to 8.09).

###### 

Multivariate analysis of risk factors for hospital mortality (*n*= 313)

  Variable                 Odds ratio   95% confidence interval   *P*value
  ------------------------ ------------ ------------------------- ----------
  Cancer                   2.82         1.24 to 6.41              0.014
  Serum albumin (mg/dl)    0.34         0.19 to 0.62              \< 0.001
  Admission SAPS II        1.03         1.00 to 1.06              0.027
  Vasopressors             2.15         0.85 to 5.41              0.105
  Mechanical ventilation   3.56         1.61 to 7.85              0.002
  Hepatic failure          18.27        3.90 to 85.61             \< 0.001
  VAP                      11.33        2.03 to 63.30             0.006
  Hypoglycemic events                                             0.009
   Mild hypoglycemia       3.43         1.51 to 7.82              0.003
   Severe hypoglycemia     2.17         0.59 to 7.94              0.244

SAPS, Simplified Acute Physiology Score; VAP: ventilator-associated pneumonia. Chi-square = 4.826 and *P*= 0.776 by Hosmer-Lemeshow goodness-of-fit test.

The overall survival rate for all enrolled patients was 45.3% (140/309) at 1 year; four patients were lost to the 1-year follow-up. Mean survival times were 225.8 ± 10.9 days, 111.1 ± 20.4 days, and 66.6 ± 24.0 days in patients with no hypoglycemia, mild hypoglycemia, and severe hypoglycemia, respectively (Figure [4](#F4){ref-type="fig"}). The 1-year survival rates were significantly lower in the mild and severe hypoglycemic groups compared with patients without hypoglycemia, and no significant difference was observed between the two hypoglycemia groups.

![**Kaplan-Meier survival analyses for 1-year cumulative survival rates**. Among the three hypoglycemia groups, patients with mild hypoglycemia had a significantly lower 1-year survival rate than did patients without hypoglycemia. BG, blood glucose. ^a^*P*\< 0.001, ^b^*P*= 0.127 vs. severe hypoglycemia.](cc11674-4){#F4}

Discussion
==========

The present study identified several important findings in patients with sepsis. First, mild hypoglycemia (defined as BG 40 to 69 mg/dl) was significantly associated with increased hospital mortality, and even a single mild hypoglycemic event showed a significant association. Second, mild hypoglycemia was significantly associated with a lower 1-year cumulative survival rate. Third, mild hypoglycemia was associated with a high rate of ICU-acquired complications during the ICU stay.

Glucose control in patients with sepsis can be challenging because they are vulnerable to hyperglycemia and hypoglycemia, which result in high GV \[[@B10]-[@B12]\]. In the present study, the median value of individual mean BG levels (177.3 mg/dl (148.8 to 205.6 mg/dl)) suggested that BG was not well controlled, and insulin treatment was inadequate in patients with sepsis. However, the rate of hypoglycemia was high. In a study by Bagshaw and colleagues, the incidence of mild hypoglycemia was 6.2% in all patients and 8.6% among the sepsis subgroup \[[@B4]\]. The authors reported that the adjusted odds ratio for hospital mortality was 1.6 (95% confidence interval, 1.4 to 1.8). Egi and colleagues \[[@B7]\] and Krinsley and colleagues \[[@B8]\], more specifically, identified that mild hypoglycemia had a greater than twofold increase in the odds of hospital mortality. These previous studies targeted all ICU patients. However, we focused on patients with sepsis and noticed that even a single mild hypoglycemic event was associated with a nearly threefold increase in hospital mortality. In particular, when we stratified sepsis patients by tertile groups of SAPS II, patients with mild hypoglycemia showed a higher mortality rate than those without hypoglycemia in each tertile group (Additional file [5](#S5){ref-type="supplementary-material"}). This finding suggests that mild hypoglycemia *per se*is associated with patient outcomes independent of disease severity. However, the multivariate analysis did not reveal a significant association between severe hypoglycemia and mortality. We believe that the small number of patients with severe hypoglycemia in our study may, in part, account for this finding. A future study with a larger number of patients is thus needed to clarify this point.

We demonstrated that the long-term survival rate was significantly lower in patients with sepsis who experienced mild hypoglycemia as compared with patients with sepsis who were not hypoglycemic (Figure [4](#F4){ref-type="fig"}). Although the authors of the Normoglycaemia in Intensive Care Evaluation - Surviving Using Glucose Algorithm Regulation (NICE-SUGAR) trial noticed that severe hypoglycemia was more frequent and that 90-day mortality was higher in the IIT group \[[@B13]\], the long-term prognosis of patients with hypoglycemia has not been well studied. The NICE-SUGAR trial found no difference between the IIT and conventional-therapy groups in rates of new organ failure; however, death from cardiovascular causes was more common in the IIT group. The present study found that mild hypoglycemia was associated with increased rates of renal, cardiac, and hepatic complications and bacteremia. Although the definitions for the ICU-acquired complications in the present study were different from those used in the VISEP and NICE-SUGAR trials \[[@B2],[@B13]\], our results are additive to those of previous studies.

GV parameters are associated with hypoglycemia and mortality \[[@B10],[@B20]\]. The results of the present study show that the SD of mean BG levels, one of three GV parameters, was a significant risk factor for hypoglycemia. GV-reduction strategies may thus be critical for decreasing hypoglycemic events and hospital mortality \[[@B20]\]. We also identified other risk factors for hypoglycemia such as diabetes, hematocrit, lactate, hepatic failure, and ventilator-associated pneumonia; however, previous studies have found renal failure, renal replacement therapy, and the use of vasopressors to be risk factors \[[@B6],[@B10]\]. Although physicians must take care in the management of patients with these risk factors, it is important that they recognize that hypoglycemia may simply represent a marker of worsening organ function \[[@B21]\].

Several factors may explain the relationship between hypoglycemia and patient outcomes \[[@B21]\]. During critical illnesses, the physiological responses induced by hypoglycemia, such as the inhibition of insulin release and increased release of glucagon, epinephrine, growth hormone, and cortisol, are frequently impaired \[[@B22],[@B23]\]. Second, the large amount of glucose administered to patients with hypoglycemia may be associated with cellular damage \[[@B24]\]. Third, hypoglycemia may cause biological toxicities, such as an increased systemic inflammatory response \[[@B25]\], cerebral vasodilation \[[@B26]\], and neuroglycopenia \[[@B27]\]. In particular, severe hypoglycemia causes an increase in extracellular glutamate and results in excitotoxicity \[[@B28]\]. However, as mentioned previously, hypoglycemia may be a marker of increasing disease severity or impending death \[[@B21]\]. Although we demonstrated that mild hypoglycemia was an independent risk factor for hospital mortality, the causal relationship is not clear.

The present study had several limitations. First, it was a retrospective study, and the number of patients was limited. The data may thus reflect unintended bias. Second, capillary blood sampling was performed in a percentage of patients using a bedside glucose analyzer, which may be associated with analytic inaccuracies in critically ill patients \[[@B29]-[@B31]\]. However, this measurement is typically used in the ICU setting. Third, BG control in this investigation was challenging, reflected by the fact that the lowest quartile of the mean BG was \< 148.8 mg/dl, while the glycemic target was \< 150 mg/dl. Fourth, although we analyzed the association between the frequency of hypoglycemia and mortality, intermittent monitoring of BG in the present study may have led to undetected hypoglycemic events. Fifth, we could not investigate the insulin dosage or nutritional support (that is, calorie intake), which can impact hypoglycemic events and patient outcomes.

Despite these limitations, our study has several major strengths. First, in contrast to previous studies, we focused on mild hypoglycemic events in patients with sepsis. Although the causal relationship is unclear, a single mild hypoglycemic event may be harmful to patients. Second, we performed various analyses to elucidate the relationship between mild hypoglycemia and patient outcome. In particular, although this is a retrospective study, we obtained 1-year survival data for most of the patients (98.7%), which we think provide credible evidence regarding long-term outcome. Future large-scale, prospective studies of patients with hypoglycemia are necessary to clarify the relationship between mild hypoglycemia and patient outcome. Furthermore, consideration of hypoglycemic conditions (spontaneous vs. iatrogenic hypoglycemia) and diabetic status is also likely to yield intriguing results.

Conclusion
==========

Mild hypoglycemia was associated with increased hospital and 1-year mortality in patients with sepsis. Furthermore, it was also associated with an increased rate of ICU-acquired complications. Physicians must thus be aware of the importance of mild hypoglycemia in patients with sepsis.

Key messages
============

• Mild hypoglycemia, defined as a BG of 40 to 69 mg/dl, was significantly associated with increased hospital mortality, and even a single mild hypoglycemic event was an independent risk factor.

• Mild hypoglycemia was significantly associated with a lower 1-year cumulative survival rate among patients with sepsis.

• Mild hypoglycemia was associated with a high rate of ICU-acquired complications during the ICU stay in patients with sepsis.
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